Nektar Therapeutics reported a significant decrease in revenue for Q2 2025, down to $11.2 million from $23.5 million in Q2 2024, primarily due to the sale of its Huntsville manufacturing facility. Despite the revenue decline, the company reduced its net loss to $41.6 million from $52.4 million in the prior year's quarter, driven by lower operating costs and expenses. The company also announced positive Phase 2b data for rezpegaldesleukin in atopic dermatitis and secured Fast Track designation for the same drug in alopecia areata.

Nektar Therapeutics reported a net loss of $50.9 million for the first quarter of 2025, or $0.24 per share, compared to a net loss of $36.8 million, or $0.19 per share, in the same period last year. Total revenue decreased to $10.5 million from $21.6 million in Q1 2024, primarily due to the sale of the Huntsville manufacturing facility. Operating costs and expenses decreased slightly to $55.0 million.

Nektar's Q4 2024 revenue was $29.2 million, up from $23.9 million in Q4 2023, driven by product sales and royalty revenue. The company achieved a net income of $7.3 million, compared to a net loss of $42.1 million in the prior year. Operating costs declined due to the sale of its Huntsville manufacturing facility, contributing to improved profitability.

Nektar Therapeutics reported third quarter 2024 financial results with revenue of $24.1 million and a net loss of $37.1 million, or $0.18 per share. The company's cash and investments in marketable securities were $249.0 million as of September 30, 2024, expected to support operations into the fourth quarter of 2026.

Nektar Therapeutics reported revenue of $23.5 million and a net loss of $52.4 million for the second quarter of 2024. The company's cash and investments are expected to support operations into the third quarter of 2026.

Nektar Therapeutics reported first quarter 2024 financial results with revenue of $21.6 million and a net loss of $36.8 million, or $0.19 loss per share. Cash and investments were $326.0 million at the end of the quarter, expected to support operations into the third quarter of 2026. The company is advancing its immunology and inflammation pipeline, with Phase 2b studies for REZPEG on track.

Nektar Therapeutics reported Q4 2023 financial results, with revenue increasing to $23.9 million compared to $22.0 million in Q4 2022. The company's cash and investments in marketable securities were $329.4 million as of December 31, 2023, expected to support operations into Q3 2026. Net loss for the quarter was $42.1 million, an improvement from the $59.7 million loss in the same period last year.

Nektar Therapeutics reported revenue of $24.1 million and a net loss of $45.8 million for the third quarter of 2023. The company's cash and investments in marketable securities were $372.7 million as of September 30, 2023, expected to support operations into mid-2026.

Nektar Therapeutics reported a revenue of $20.5 million and a net loss of $51.1 million, or $0.27 loss per share, for the second quarter of 2023. The company's cash and investments in marketable securities were $409.4 million as of June 30, 2023, which are expected to support operations into at least the middle of 2026.

Nektar Therapeutics reported a revenue of $21.6 million for Q1 2023, compared to $24.8 million in Q1 2022. The net loss for the quarter was $137.0 million, or $0.73 loss per share, as compared to a net loss of $90.4 million, or $0.49 loss per share, in Q1 2022. Cash and investments in marketable securities were $456.8 million at the end of the quarter.

Nektar Therapeutics reported a decrease in revenue for Q4 2022 compared to Q4 2021, driven by a decrease in non-cash royalty revenue. The company is focused on reducing operating costs to extend its cash runway through at least the middle of 2025. Net loss decreased compared to the same period last year.

Nektar Therapeutics reported a revenue of $23.6 million and a net loss of $59.0 million for the third quarter of 2022. The company's cash and investments in marketable securities were approximately $546.4 million as of September 30, 2022, expected to support strategic development activities and operations through the middle of 2025.

Nektar Therapeutics reported a decrease in revenue and a net loss for Q2 2022, impacted by restructuring costs related to the wind down of the bempegaldesleukin program. The company is focusing on its biologic therapeutic candidates, NKTR-358 and NKTR-255, and has sufficient capital to fund its pipeline.

Nektar Therapeutics reported revenue of $24.8 million and a net loss of $90.4 million for the first quarter of 2022. The company's cash and investments in marketable securities were approximately $704.4 million as of March 31, 2022, expected to support operations into 2025. A new strategic plan refocuses the company around specific investment into its most important pipeline programs.

Nektar Therapeutics reported revenue of $25.0 million and a net loss of $145.6 million for the fourth quarter of 2021. The company's cash and investments in marketable securities were approximately $0.8 billion at the end of the year. Nektar is advancing its clinical pipeline in oncology, immunology, and virology.

Nektar Therapeutics reported revenue of $24.9 million and a net loss of $129.7 million for the third quarter of 2021. The company's cash and investments in marketable securities were approximately $955.3 million as of September 30, 2021.

Nektar Therapeutics reported a decrease in revenue for Q2 2021 compared to Q2 2020, primarily due to the recognition of a $25.0 million milestone from Bristol-Myers Squibb in the previous year. The net loss also increased, driven by higher operating costs and expenses.

Nektar Therapeutics reported a decrease in revenue for Q1 2021, with $23.6 million compared to $50.6 million in Q1 2020. The net loss for the quarter was $123.0 million, or $0.68 per share, compared to a net loss of $138.7 million, or $0.78 per share, in the same quarter of the previous year. Cash and investments in marketable securities were approximately $1.1 billion as of March 31, 2021.

Nektar Therapeutics reported Q4 2020 revenue of $23.5 million compared to $33.9 million in Q4 2019. The net loss for the quarter was $117.2 million, or $0.65 loss per share, compared to a net loss of $112.2 million, or $0.64 loss per share in Q4 2019.

Nektar Therapeutics reported revenue of $30.0 million and a net loss of $108.6 million for the third quarter of 2020. The company's cash and investments in marketable securities were approximately $1.2 billion as of September 30, 2020.

Nektar Therapeutics reported revenue of $48.8 million for Q2 2020, compared to $23.3 million in Q2 2019. The increase was due to the recognition of a $25.0 million milestone from Bristol-Myers Squibb. Net loss for the quarter was $80.0 million, or $0.45 loss per share, compared to a net loss of $110.3 million, or $0.63 loss per share in Q2 2019. The company ended the quarter with approximately $1.2 billion in cash and investments.

Nektar Therapeutics reported Q1 2020 financial results, with revenue increasing to $50.6 million compared to $28.2 million in Q1 2019, primarily due to a milestone payment from Bristol-Myers Squibb. The net loss for the quarter was $138.7 million, or $0.78 per share, compared to a net loss of $119.6 million, or $0.69 per share, in Q1 2019. The company's cash and investments in marketable securities were approximately $1.5 billion as of March 31, 2020.

Nektar Therapeutics reported a revenue of $33.9 million for the fourth quarter of 2019, compared to $39.8 million in the fourth quarter of 2018. The net loss for the quarter was $112.2 million, or $0.64 loss per share, compared to a net loss of $98.2 million, or $0.57 loss per share in the fourth quarter of 2018.